Xintela taking EQSTEM, a stem cell product for horses, towards the market
In a recently completed study in horses, the stem cell product EQSTEM® shows significantly reduced lameness in horses with osteoarthritis (OA) due to joint injury, indicating that this product can reduce joint pain and improve joint function. Xintela is now taking EQSTEM further to the animal health market and will, in dialogue with EMA (European […]
Targinta selects lead drug candidate for triple-negative breast cancer
The preclinical stage oncology biotech company Targinta has selected its first lead drug candidate, TARG10, a therapeutic antibody targeting integrin a10b1. TARG10 has shown strong activity on cancer cells and in preclinical tumor models, with significant inhibitory effects on both growth and metastasis in triple-negative breast cancer models. Xintela, of which Targinta is a wholly […]
Xintela to expand clinical development of stem cell product XSTEM
Lund, Sweden, September 30 2021 – Xintela announces it will expand clinical development of its stem cell product XSTEM to the next chosen indication venous leg ulcers, the most common type of difficult-to-heal (chronic) wounds in humans. A scientific advice meeting with the Swedish Medical Products Agency (MPA) has been successfully completed and preparation of […]
Xintela Half-year Report 2021-01-01 – 2021-06-30
Summary of the half-year report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Second quarter 1 April – 30 June 2021 · Income amounted to TSEK 0 (0). · Loss before tax totalled TSEK 11,797 (loss: 9,087). · Loss per share* was SEK 0.13 (loss: 0.22). · At 30 June […]
Closing in on our next major milestone
Closer to clinical trials We are now closing in on our next major milestone: initiating clinical trials with the stem cell product XSTEM. Many pieces of the puzzle have fallen into place for us to get this far, each of which reflects a great deal of hard, goal-oriented work by our team. Some of […]
Xintela signs with Australian CRO for clinical study
Xintela announces today that the company has signed a contract with GreenLight Clinical, an Australian Contract Research Organisation (CRO) to conduct Xintela’s First-in-Human study using the stem cell product XSTEM. Xintela’s First-in-Human study with the stem cell product XSTEM, a combined phase I/II clinical study on patients with knee osteoarthritis, will be conducted in Australia […]
Xintela incorporates subsidiary in Australia
Xintela has formed a wholly owned subsidiary, Xindu Pty Ltd, in Australia, which will administer the company’s upcoming clinical study on osteoarthritis patients. Xintela has previously announced that the company is planning a clinical study (Phase I / IIa) in Australia where the stem cell product XSTEM® will be tested for the treatment of osteoarthritis. […]
Xintela has completed a directed new share issue raising proceeds of approximately SEK 28 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, FULLY OR PARTLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, CANADA, JAPAN, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE […]
Xintela intends to carry out a directed share issue through an accelerated book building procedure
Lund, 2021-06-16 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, FULLY OR PARTLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, CANADA, JAPAN, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE […]
Xintela’s GMP facility approved for manufacturing of cell therapy products
Xintela announces today that the company has received permission from the Medical Products Agency to produce cell therapy products, so-called advanced therapy drugs (ATMPs), in its own GMP facility. – It is a key achievement from the team that the manufacturing permit is now in place. This means we can now start to manufacture our […]
